Tissue partitioning can alter concentrations in which compartments, affecting efficacy or toxicity risk?

Tissue partitioning can alter concentrations in which compartments, affecting efficacy or toxicity risk?

• A. CNS and Liver
• B. Skeletal Muscle Only
• C. Plasma Only
• D. Kidneys Only

Answer: (A)

Tissue partitioning describes how a drug distributes between plasma and various tissues, so the actual concentration in each compartment depends on properties like lipophilicity, ionization, binding, perfusion, and transport processes. This distribution matters because it determines where the drug can exert its effects—and where it might cause toxicity. The central nervous system is a key compartment because crossing the blood-brain barrier is highly selective. If a drug partitions into the CNS, it can produce therapeutic CNS effects, but it can also cause CNS toxicity. So changes in CNS partitioning directly impact efficacy and safety. The liver is another major site because it is highly perfused and rich in metabolic enzymes. Partitioning into liver tissue determines how much of the drug is exposed to hepatocytes, affecting metabolism, formation of active or toxic metabolites, and risk of liver injury. Among the given options, these two compartments best capture where tissue partitioning has clear consequences for both efficacy and toxicity, making them the best match. Other compartments like skeletal muscle, plasma, or kidneys can be affected by distribution as well, but they don’t single out the same direct implications for efficacy and toxicity as CNS and liver.

Tissue partitioning describes how a drug distributes between plasma and various tissues, so the actual concentration in each compartment depends on properties like lipophilicity, ionization, binding, perfusion, and transport processes. This distribution matters because it determines where the drug can exert its effects—and where it might cause toxicity.

The central nervous system is a key compartment because crossing the blood-brain barrier is highly selective. If a drug partitions into the CNS, it can produce therapeutic CNS effects, but it can also cause CNS toxicity. So changes in CNS partitioning directly impact efficacy and safety.

The liver is another major site because it is highly perfused and rich in metabolic enzymes. Partitioning into liver tissue determines how much of the drug is exposed to hepatocytes, affecting metabolism, formation of active or toxic metabolites, and risk of liver injury.

Among the given options, these two compartments best capture where tissue partitioning has clear consequences for both efficacy and toxicity, making them the best match. Other compartments like skeletal muscle, plasma, or kidneys can be affected by distribution as well, but they don’t single out the same direct implications for efficacy and toxicity as CNS and liver.